Selected article for: "antibody titer and challenge virus"
Author: Jadi, R.S.; Sudeep, A.B.; Barde, P.V.; Arankalle, V.A.; Mishra, A.C.
Title: Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus)
  • Cord-id: ikq9t2v7
  • Document date: 2011_6_20
    • ID: ikq9t2v7
    Snippet: A Vero cell based vaccine candidate against Chandipura (CHP) virus (Rhabdoviridae: Vesiculovirus), was developed and evaluated for immunogenicity in mice. Virus was purified by ultracentrifugation on 30% glycerol cushion followed by differential centrifugation on 10–60% sucrose gradient and inactivated with β-propio lactone at a concentration of 1:3500. The inactivated product was blended with aluminium phosphate (3%) and immunized 4-week-old Swiss albino mice. Neutralizing antibodies in the
    Document: A Vero cell based vaccine candidate against Chandipura (CHP) virus (Rhabdoviridae: Vesiculovirus), was developed and evaluated for immunogenicity in mice. Virus was purified by ultracentrifugation on 30% glycerol cushion followed by differential centrifugation on 10–60% sucrose gradient and inactivated with β-propio lactone at a concentration of 1:3500. The inactivated product was blended with aluminium phosphate (3%) and immunized 4-week-old Swiss albino mice. Neutralizing antibodies in the range of 1:10 to 160 and 1:80 to 1:320 was detected with 85% and 100% sero-conversion after 2nd and 3rd dose, respectively. All the immunized mice with antibody titer above 1:20 survived live virus challenge. The vaccine candidate has potential to be an efficient vaccine against CHP virus.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and additional set: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and live virus challenge: 1
    • acute respiratory syndrome and low pathogenicity: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lymphatic system: 1, 2
    • live virus and low pathogenicity: 1, 2, 3, 4